Lars Kjeldsen

American Pharmacists Association — United States

Medicine · Health Sciences

55h-index12.5kcitations173works7.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(58), Acute Lymphoblastic Leukemia research(22), Neutrophil, Myeloperoxidase and Oxidative Mechanisms(18), S100 Proteins and Annexins(18), Neutropenia and Cancer Infections(18)

Publications172 total

Development of my medication plan involving patients and patient representatives as co-designers
Pharmacy Practice·2025Open Access
Outpatient Management of Patients Conditioned with Fludarabine and Treosulfan prior to Allogeneic Hematopoietic Cell Transplantation
Transplantation and Cellular Therapy·2024· 2 citedOpen Access
Do Older Patients With Hematological Malignancy Benefit From Exercise Interventions? A Systematic Review And Meta-analysis
Medicine & Science in Sports & Exercise·2024
It is feasible and safe to stop specialized follow-up of asymptomatic lower-risk chronic lymphocytic leukemia
Blood Advances·2024· 4 citedOpen Access
Family caregiver quality of life and symptom burden in patients with hematological cancer: A Danish nationwide cross-sectional study
European Journal of Oncology Nursing·2024· 6 citedOpen Access
A randomised evaluation of <scp>low‐dose</scp> cytosine arabinoside plus lenalidomide versus <scp>single‐agent low‐dose</scp> cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the <scp>LI</scp> ‐1 trial
British Journal of Haematology·2023Open Access
Family caregiver ambassador support for caregivers of patients with newly diagnosed hematological cancer: a feasibility study
Supportive Care in Cancer·2022· 18 citedOpen Access
A randomised comparison of <scp>FLAG‐Ida</scp> versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the <scp>UK NCRI AML17</scp> trial
British Journal of Haematology·2022· 4 citedOpen Access
Treatment intensification with FLAG‐Ida may improve disease control in younger patients with secondary acute myeloid leukaemia: long‐term follow up of the MRC AML15 trial
British Journal of Haematology·2021· 16 citedOpen Access
A national Danish proof of concept on feasibility and safety of home -based intensive chemotherapy in patients with acute myeloid leukemia
Leukemia Research·2021· 15 cited
A Randomised Evaluation of Low-Dose Cytarabine Arabinoside Plus Lenalidomide Versus Single-Agent Low-Dose Cytarabine Arabinoside in Older Patients with Acute Myeloid Leukaemia: Results from the LI-1 Trial
Blood·2021· 3 cited
Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial
Haematologica·2021· 29 citedOpen Access
Longitudinal symptom burden in adult patients with acute leukaemia participating in the PACE‐AL randomised controlled exercise trial—an explorative analysis
European Journal of Cancer Care·2021· 6 cited
Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses
Journal of Clinical Oncology·2020· 27 citedOpen Access
Patient ambassador support in newly diagnosed patients with acute leukemia during treatment: a feasibility study
Supportive Care in Cancer·2020· 14 citedOpen Access
Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome
Leukemia·2020· 27 citedOpen Access
The HemoScreen hematology point‐of‐care device is suitable for rapid evaluation of acute leukemia patients
International Journal of Laboratory Hematology·2020· 8 citedOpen Access
Patient ambassador support: Experiences of the mentorship between newly diagnosed patients with acute leukaemia and their patient ambassadors
European Journal of Cancer Care·2020· 16 citedOpen Access
Erratum to “Patients experiences and social support needs following the diagnosis and initial treatment of acute leukemia - A qualitative study” [Eur. J. Oncol. Nurs. 41 (2019) 49–55]
European Journal of Oncology Nursing·2019Open Access
PF264 TREATMENT INTENSIFICATION WITH FLAG‐IDA MAY IMPROVE DISEASE CONTROL IN YOUNGER PATIENTS WITH SECONDARY AML WHICH MANIFESTS ITSELF WITH LONGER FOLLOW‐UP: LONG‐TERM ANALYSIS OF THE MRC AML15 TRIAL
HemaSphere·2019Open Access
page 1 of 9Next →

Frequent Co-authors

Niels Borregaard(33), Henrik Sengeløv(18), Robert K. Hills(6), Nigel H. Russell(6), Alan K. Burnett(5), Maxwell Sehested(5), Jack B. Cowland(5), Anders H. Johnsen(5), Lene Udby(5), Donald Milligan(4), Jonathan Kell(3), Keith Wheatley(3), DF Bainton(3), Karsten Lollike(3), D F Bainton(3), Tobias Wirenfeldt Klausen(3), Henrik Birgens(3), Ole Weis Bjerrum(3), Ole E. Sørensen(3), Anthony H. Goldstone(2)